Editorials:

Classification and prognosis of systemic vasculitis by D. G. I. Scott 251
Sjögren's syndrome: a human model of autoimmunity and malignancy by H. M. Moutsopoulos and A. P. Andonopoulos 253
Clinical findings and prognosis of polyarteritis nodosa and Churg–Strauss angiitis: a study in 165 patients by L. Guillemin, L. Thi Huong Du, P. Godeau, P. Jais and B. Wechsler 258
Sjögren's syndrome: a study of its neurological complications by A. Binder, M. L. Snaith and D. Isenberg 275
An epidemiological study of scleroderma in the West Midlands by A. Silman, S. Jannini, Deborah Symmons and P. Bacon 286
The effect of indomethacin and aspirin on alkaline phosphatase secretion and [3H]thymidine incorporation by human osteoblasts by M. A. Khokher and P. Dandona 291
Outpatient lumbar epidural corticosteroid injection in the management of sciatica by M. G. Ridley, Gabrielle H. Kingsley, T. Gibson and R. Grahame 295
Brief Report:

Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double-blind trial by Ursula M. Davies, R. G. Palmer and A. M. Denman 300
Clinical Practice:

Anaemia in patients with arthritis: are simple investigations helpful? by A. Doube and A. J. Collins 303

Viewpoint:

The role of HLA-B27 in arthritis by J. R. Archer, V. R. Winrow and I. L. McLean 306
British Society for Rheumatology Annual General Meeting Symposia Reports:

Polymyalgia rheumatica and giant-cell arteritis by H. A. Bird 310
Biomechanics by G. R. Johnson 312
Cell growth and activation by J. A. Symons 314
Case Reports:

Bilateral hypoglossal nerve palsy due to vertical subluxation of the odontoid process in rheumatoid arthritis by T. F. Macedo, P. J. Gow, S. W. Heap and W. E. Wallis 317

Letters to the editor:

Prolactin secretion in rheumatoid arthritis by I. C. Chikanza and G. S. Panayi 324; Dr. Berczi and colleagues reply by I. Berczi, H. Cosby, T. Hunter, F. Baragar, H. G. Friesen and A. S. McNeilly 324; New consultant's workshop in rheumatology by D. L. Scott, R. C. Butler and M. S. Irani 325; The 'questionnaire' versus the 'direct observation' approach to functional assessment by M. Dorevitch 326; Dr. McFarlane and Prof. Brooks reply by A. C. McFarlane and P. M. Brooks 326; The role of a rheumatologist by C. W. Hutton 327; Diffuse idiopathic skeletal hyperostosis misdiagnosed as ankylosing spondylitis by J. M. Findeisen and R. B. Claque 327; The genetics of osteoarthritis of the hand by D. C. Macfarlane, C. Buckland-Wright and B. Clark 328; Vitamin A in osteo- and rheumatoid arthritis by Angela Fairney, K. V. Patel, D. E. Fish and M. H. Serfert 329; Synovial fluid crystals by D. R. Swinson, K. Gill and P. Howard 330; Anterior chest wall deformities associated with juvenile onset of a chronic arthritis by A. N. Graham and M. R. Laurent 330; Back pain and sciatica by J. A. Mathews 331; Haemophilia and rheumatoid arthritis by D. Collins and B. E. Bourke 332; Rheumatology in general practice by P. Jobanputra 332
Reviews of Books 334

Obituary:

Dr. Logie Samuel Bain 336

ISSN 0263-7103

SEP 01 1988

FAMILY HEALTH FOUNDATION

Official Journal of the British Society for Rheumatology published by Baillière Tindall · London
ESSENTIAL INFORMATION FOR CONTRIBUTORS

1. The BRITISH JOURNAL OF RHEUMATOLOGY is the official Journal of the British Society for Rheumatology. It publishes original papers and correspondence concerning all aspects of rheumatology. Articles on clinical, laboratory and therapeutic research are especially welcome.

2. Manuscripts: Papers are accepted on condition that their major content has not been, nor will be, published elsewhere. Manuscripts must be typewritten with double spacing and wide margins. Authors should strive for brevity and a concise use of English.

The presentation of original work should conform to ‘Uniform requirements for manuscripts submitted to biomedical journals’ (British Medical Journal 1982;284;1766-70). This covers details of title page, summary, key words, text, tables, illustrations, legends and abbreviations. Begin each of the following sections on separate pages: title page, summary, text, acknowledgements, references, individual tables and figure legends. Number pages consecutively beginning with the title page. The summary should not exceed 150 words and should be followed by up to 10 key words. Statistical methods must be detailed. Papers are accepted on the understanding that they may be subjected to editorial revision. Three copies of each manuscript and accompanying tables, graphs and illustrations should be sent to The Editor, British Journal of Rheumatology, Guy's Hospital, London SE1 9RT, UK. In the event of rejection, one copy of the manuscript and accompanying material will be returned. Every contributor on the title page of a manuscript must authorize permission to publish by signing an appropriate letter.

3. References in the text should be given as numbers in brackets, placed in line with the text and in order of appearance. They should be listed in numerical order at the end of the paper. All authors should be included in a reference when there are six or less but only the first three followed by et al. when there are seven or more. Authors' names should be followed by the title of article, abbreviated name of journal (a list is given in each January issue of Index Medicus), year, volume and first and last page numbers. References to books should state the author, followed by a chapter title, editors' names, book title, places of publication, publisher, year and appropriate page numbers. For punctuation of references, consult a current issue of this Journal.

4. Figures: All graphs and illustrations should be submitted as glossy black and white prints. Slides, negatives, radiographs and photocopies are not acceptable. Authors are reminded that figures are reduced in size on publication and labelling should be large, even and clear. Each figure should be marked on the back in soft pencil with its number, first author and top edge. Any previously published material should be accompanied by the permission of the author and copyright holder for its reproduction. Figure legends should be typed on a separate sheet. Details of photomicrographs should include the original magnification.

5. Proofs: The first named or a nominated author will be sent proofs for minor corrections. Major alterations will be charged to the author.

6. Reprints. 50 of each article are supplied free to the author named as correspondent. Costs of additional reprints are supplied with the proofs and orders should be returned to the publisher. Payment must be made with the order.

7. Advertising and business communications should be sent to the publishers, Bailliere Tindall, 24–28 Oval Road, London NW1 7DX.

The full text of this journal is now available on Colleague, the online medical literature and information retrieval service for health care professionals. For more information contact BRS/Saunders Colleague, Suite 1200, 1290 Avenue of the Americas, New York, N.Y. 10104, U.S.A.

The journal is also listed in Current Contents/Life Sciences/Clinical Practice • Index Medicus • Excerpta Medica.

© 1988 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying or otherwise, without the prior permission of the Editor and publishers of the Journal. Requests in the first place to Bailliere Tindall. Articles are accepted on the understanding that any sale of rights for translation or re-publication will be negotiated by the publishers on behalf of the author, and that the net proceeds of any such sale (other than to the author) will be divided equally between the author(s) and publishers.

BRITISH JOURNAL OF RHEUMATOLOGY: ISSN 0263-7103. Volume 27, 1988. published bi-monthly by Bailliere Tindall, at 24–28 Oval Road, London NW1 7DX. UK. Annual subscription price including postage: £48 and US $95 overseas. Subscription orders should be sent to Bailliere Tindall, Academic Press Ltd., Footscray High Street, Sidcup, Kent DA14 5HP, UK (01-300 3322). Send notices of change of address to the publisher at least 6–8 weeks in advance, including both old and new address.

Application to mail at second class postage rate is pending at Jamaica, NY 11431, USA.

Air freight and mailing in the USA by Publications Expediting Inc., 200 Meacham Avenue, Elmont, NY 11003, USA.

USA POSTMASTERS: send change of addresses to BRITISH JOURNAL OF RHEUMATOLOGY, c/o Publications Expediting Inc.

Printed in UK.
Salazopyrin EN-tabs has a favourable benefit: risk ratio for early intervention when NSAIDs alone prove inadequate, and because it works promptly, patients improve early — often within one month.

Salazopyrin®
enteric coated sulphasalazine

Positive action in rheumatoid arthritis
Every move she makes.

Feldene in chronic arthritis.

Continuous relief from a single daily dosage.

PRESCRIBING INFORMATION

Indications: Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout, acute musculoskeletal disorders and children with definitely diagnosed juvenile chronic arthritis (Still's disease). Dosage: Rheumatoid arthritis: osteoarthritis and ankylosing spondylitis. Normal starting and maintenance dosage 20mg once daily. Long-term use of 30mg daily carries an increased risk of gastro-intestinal side-effects. Acute gout: 40mg daily in single or divided doses for up to 7 days. Acute musculoskeletal disorders: 40mg daily, in single or divided doses, for the first 2 days, 20mg daily for the remainder of the 7 to 14 day treatment. Juvenile chronic arthritis in children aged 6 years and older: Feldene dispersible tablets using the following dosage schedule: less than 15kg body weight: 5mg, 16-25kg body weight: 10mg, 26-45kg body weight: 15mg, 46kg body weight and above: 20mg.

Contraindications: Active peptic ulceration or history of recurrent ulceration. Hypersensitivity to Feldene, aspirin or other NSAIDs. Suppositories - patients with a history of inflammatory lesions or bleeding of the rectum or anus. Warnings: Pregnancy, lactation. As with other NSAIDs, elderly patients should be closely supervised.

Precautions: Significant renal impairment. Monitor patients on concurrent anticoagulants. Concurrent use of aspirin or other NSAIDs not advised.

Side Effects: Gastro-intestinal symptoms; if peptic ulceration or gastro-intestinal bleeding occurs withdraw FELDENE. Oedema, mainly ankle. Skin rashes.

Package Quantities and Basic NHS Cost: Capsules 10mg, pack of 60 £9.50 (PL57/0145); capsules 20mg, pack of 30 £9.50 (PL57/0146); dispersible tablets 10mg, pack of 60 £10.45 (PL57/0240); dispersible tablets 20mg, pack of 30 £10.45 (PL57/0242); suppositories 20mg, pack of 10 £5.20 (PL57/0219).

Full information on request.